Pfizer Inc. $PFE Shares Sold by Straight Path Wealth Management

Straight Path Wealth Management cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 43.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 53,564 shares of the biopharmaceutical company’s stock after selling 40,952 shares during the period. Pfizer makes up about 0.4% of Straight Path Wealth Management’s portfolio, making the stock its 28th largest holding. Straight Path Wealth Management’s holdings in Pfizer were worth $1,334,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Horizon Financial Services LLC grew its position in shares of Pfizer by 174.8% during the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the period. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. YANKCOM Partnership purchased a new stake in shares of Pfizer during the 4th quarter valued at approximately $28,000. HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 427 shares during the period. Finally, Darwin Wealth Management LLC purchased a new stake in Pfizer in the second quarter valued at approximately $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer highlighted fresh oncology progress, including new and advancing clinical studies in lung cancer and bladder cancer, which could strengthen its long-term cancer pipeline if the early data continue to trend well. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
• Positive Sentiment: The company also expanded its oncology pipeline with a new combination trial in advanced lung cancer, reinforcing the market’s view that cancer treatments remain a key growth area for Pfizer. Pfizer Expands Oncology Pipeline With New PF-08634404 Combo Trial in Advanced Lung Cancer
• Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to use AI for drug discovery, signaling a push to speed up research and improve pipeline productivity over time. Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI
• Neutral Sentiment: Pfizer and Astellas advanced an early bladder cancer combination trial, which is encouraging scientifically but still too early to materially change near-term financial expectations. Pfizer and Astellas Advance New Bladder Cancer Combo in Early Clinical Trial
• Neutral Sentiment: Pfizer’s conference presentation and several study updates on tofacitinib and bevacizumab biosimilars are incremental developments, but they are unlikely to move the stock on their own. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Investor sentiment is still being weighed down by concerns that Pfizer is down about 4.5% since its last earnings report, suggesting the market remains focused on slower post-earnings momentum and earnings estimate pressure. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PFE shares. CICC Research started coverage on Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Morgan Stanley boosted their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Finally, Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price on the stock. in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Stock Performance

NYSE:PFE opened at $25.70 on Friday. The company has a fifty day simple moving average of $26.65 and a two-hundred day simple moving average of $26.29. The company has a market cap of $146.46 billion, a price-to-earnings ratio of 19.62 and a beta of 0.34. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. Pfizer Inc. has a 52 week low of $23.08 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s payout ratio is 131.30%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.